Syngene International Ltd. · NSE:SYNGENE
Syngene International — Investor Presentation (February 2016)
31 slides from Syngene International's investor presentation, Feb 22, 2016
Slide 1: Investors Presentation cover letter to BSE and NSE
Syngene Ref: Syn/Acts/CS/SE/Ltrs-BSE/NSE Syngene International Limited SEZ Unit, Biocon Special Economic Zone Bommasandra-Jigani Link Road Bangalore 560 099, India February 22, 2016 T 91 80 2808 2808 F 91 80 2808 3189 CIN : U51909KA1993PLC014937 To www.syngeneintl.com The BSE Limited, The National S
Slide 2: Investor Presentation February 2016
Investor Presentation Feburary 2016 Strictly confidential & privileged
Slide 3: Safe Harbour
Safe Harbour Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking statements
Slide 4: Introduction
Introduction Putting Science to Work
Slide 5: Introduction
Introduction The Biocon Group Syngene’s Shareholding Pattern1 Services Based Biocon ESOP Contract Discovery 1.0% Contract Development Syngene ESOP 3.1% Contract Manufacturing Promoter 73.6% Public Product Based 22.4% Silver leaf : 10% Biosimilars Others: 12.4% Formulations and Compound
Slide 6: Overview
Overview o Established in 1994 as India’s first Contract Research Organization – 21+ years of unparalleled experience in novel molecule discovery & development services o Integrated Service Platform for small & large molecules including Antibody-drug conjugates and oligonucleotides o World class Inf
Slide 7: Recent Business Highlights
Recent Business Highlights All figures in INR Mn unless otherwise specified Cleared a USFDA audit in Q3FY16 of our clinical P&L Summary 9M FY16 9M FY15 YoY Change development facility. Revenue 7,789 6,175 26% Successfully cleared 5 US FDA audit of our facilities EBITDA 2,581 2,071 25% EBITDA Mar
Slide 8: Journey Over the Years
Journey Over the Years 20,000 sq ft facility Over 900,000 sq ft facility Infrastructure 100+ 2,800+ People - Chemistry - Preliminary biology - End-to-End discovery, development and manufacturing capabilities Capabilities $5 million $150 million Investment 7 Strictly confidential & privileged
Slide 9: Who We Are Today: A Global High Growth CRO Company
Who We Are Today: A Global High Growth CRO Company One of the leading India-based CROs Strong Growth and Profitability Integrated discovery and development platform Focus on novel molecular entities 8,716 221(1) clients across multiple sectors 7,077 5,542 95%(1) of revenues from outside India 4,182
Slide 10: Putting Science to Work
Putting Science to Work Who we are and what we do Combining world class research talent and infrastructure with the Indian cost advantage Converting R&D to a variable cost for clients Moving beyond cost arbitrage to R&D productivity and innovation Key Differentiators of Growth Scalable Predict
Slide 11: Our Industry
Our Industry Putting Science to Work
Slide 12: Global Pharma R&D Trends
Global Pharma R&D Trends Large and growing addressable market Industry Statistics Global R&D expenditure expected to increase from (US$ bn) $139bn in 2014 to $152bn in 2018 (CAGR of 2.3%) Global R&D Spending Global CRO Market(1) 75% of R&D spend can be potentially outsourced Increasing per u
Slide 13: Global CRO Market: Over US$43bn and Growing
Global CRO Market: Over US$43bn and Growing Outsourcing Market by Stage of DD Continuum Significant Growth in APAC (US$bn) Global NME Discovery Outsourcing Market (US$bn) 67.2 22.7 15.2 43.4 14.7 15.2 9.2 24.7 15.8 4.6 10.5 3.8 22.7 7.5 14.7 4.2 2014 2018 2014 2018 Discovery Preclinical Clinical (Ph
Slide 14: Business Overview
Business Overview Putting Science to Work
Slide 15: The Drug Discovery Continuum
The Drug Discovery Continuum Discovery Development Commercialisation Pre- clinical Clinical Target Lead Product Animal Ph Ph Ph Drug filing launch Identification Generation with FDA & Lead Safety I II III other global Selection regulatory Target Target API and Drug product authorities Marketing/ Dev
Slide 16: Fully Integrated Services Platform
Fully Integrated Services Platform… Discovery Development Manufacturing Drug Substance Chemistry Development Clinical Supplies Small Molecules Drug Product Development Biology Integrated Drug Substance – Specialty Molecules Drug Product Integrated drug discovery Clinical Services (India) Commercial
Slide 17: With Multiple Entry Points
…With Multiple Entry Points Discovery Development Commercialisation Pre- clinical Clinical Target Lead Product Animal Ph Ph Ph Drug filing launch Identification Generation with FDA & Lead Safety I II III other global Selection regulatory Target Target API and Drug product authorities Marketing/ Deve
Slide 18: Integrated Platform to Build Strategic Relationships
Integrated Platform to Build Strategic Relationships Customer Focus Cost Arbitrage R&D Productivity Innovation Multiple Services Dedicated Play Integrated Play Capabilities/ Complexity Cluster Plays Component Plays Single Service Small/Short Term Scale/Predictability Larger/Long Term 17
Slide 19: Verticals Overview
Verticals Overview Dedicated centers Discovery Services Development & • Integrated Services • Discovery Chemistry, Discovery Manufacturing Services • Dedicated Infrastructure Biology and in-vivo services • Preclinical studies, Stability, customized for client’s • Multi-client infrastructure formulat
Slide 20: Dedicated Centres: Long term relationships
Dedicated Centres: Long term relationships Largest R&D Centre in Asia for BMS Dedicated research centre in India for Abbott Nutrition’s 1st R&D centre in India (2009). Contract extended till 2020. Baxter (2013). set up in collaboration with Syngene (2012). Dedicated centre of research excellence Sta
Slide 21: Discovery Services: From Target to a Drug Candidate
Discovery Services: From Target to a Drug Candidate Candidate Hit to Lead Lead Optimization Development Selection Candidate Candidate 5 Lead Selection Development Compounds Exploratory PK, Tox & Developability Assessment 20 Lead In-Vivo DMPK Profiling, Compounds CADD 500 Lead Generation of focused C
Slide 22: Development Services
Development Services Encompass activities across multiple disciplines as a molecule moves from pre-clinical to clinical trials Preclinical Clinical Key activities include: Studies Studies Drug o Drug substance development (process r&d and product Dvpt. optimization) Drug Substance o Drug product
Slide 23: Manufacturing Services
Manufacturing Services Small • A State-of-the-art cGMP facility to Manufacture NCEs Molecules • Designed to support multi gram to 100s of kgs/ batch of Intermediates, & APIs for Clinical Trials; Current capacity can support initial commercial supplies • New greenfield investment being made in Mangal
Slide 24: Multiple Layers of Growth
Multiple Layers of Growth Expand/Extend existing clients Capacity Expansion - High service integration - Consistent expansion - Dedicated centres model - FTE services, manufacturing, formulation, biologics, stability Engage New Clients - Tailored service offerings and Customer Capacity dedicated per
Slide 25: Financial Highlights
Financial Highlights Putting Science to Work
Slide 26: YTD FY16 Financial Highlights
YTD FY16 Financial Highlights All figures in INR Mn unless otherwise specified 9M FY16 9M FY15 YoY Change Balance Sheet Highlights Revenue 7,789 6,175 26% Material & Power costs 2,411 1,931 25% As on 31st December 2015 Employee costs 1,757 1,491 18% 10,054 Gross Margin 3,621 2,753 32% Shareholders’
Slide 27: Strong Track Record Of Topline Growth
Strong Track Record Of Topline Growth… Growth driven by increase in sales from Total Revenue (INR Mn) existing clients and acquisition of new clients “Engage, expand and extend” strategy to extend client relationship over a longer period 8,716 7,789 of time 7,077 Growth in total number of clie
Slide 28: With Best-in-Class Profitability
…With Best-in-Class Profitability Operating Margin (EBITDA) Profit After Tax Margin (Net Income) 20% 20% 34% 34% 33% 19% 17% 18% 31% 31% 30% 1,750 2,928 1,547 2,581 9% 1,339 2,217 1,682 976 1,404 727 1,005 283 FY2011 FY2012 FY2013 FY2014 FY2015 9M FY2016 FY2011 FY2012 FY2013 FY2014 FY2015 9M FY2016
Slide 29: Capital Expenditure
Capital Expenditure Historical Capital Investments – Average Gross Block (INR Mn) Planned Capital Expenditure 8,255 Capex of US$200 million envisaged over FY16 to FY18 6,149 6,819 5,610 5,216 Future funding requirements to be met through internal accruals & debt Capex investment area FY2011 FY20
Slide 30: Managing Risks
Managing Risks Risk Mitigation Client growth and sustained retention Proactive client engagement and sustained quality Comprehensive hedging policy and tracking mechanism Currency fluctuation (USD/INR) in place Significant capex investment over next few years Staggered investments in line with busin
Slide 31: Thank You
THANK YOU For more details www.syngeneintl.com • Visit www.syngeneintl.com • IR Contact : Sweta Pachlangiya +91 80 2808 5481 sweta.pachlangiya@syngeneintl.com
Syngene International — Investor Presentation (February 2016) on 6ix